The Mayo Lung Cohort: A Regression Analysis Focusing on Lung Cancer Incidence and Mortality PURPOSE: Lymph node metastases are the most significant prognostic factor in localized non–small-cell lung ...
Studies in breast cancer, melanoma, colon cancer, lung cancer and almost all solid malignancies that spread to lymph nodes have confirmed that metastatic cells move in an orderly manner from the ...
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the ...
September 11, 2012 — Approval of technetium (99m Tc)-tilmanocept for injection (Lymphoseek, Navidea), a product developed for intraoperative lymphatic mapping (ILM) in breast cancer and melanoma ...
Navidea Biopharmaceuticals announced results from two Phase 3 clinical trials of Lymphoseek (technetium 99m tilmanocept) Injection in patients with melanoma of the skin, assessing the performance of ...
FDA Approves Navidea's Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Ma
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced U.S. Food and Drug ...
Near-infrared (NIR) fluorescence imaging has been demonstrated to be feasible during cancer surgery using available imaging systems and contrast agents Clinical applicability has been described in ...
A novel receptor-targeted radioactive tracer for intraoperative lymphatic mapping (ILM) — technetium Tc 99m tilmanocept (Lymphoseek, Navidea Biopharmaceuticals) — has been approved by the US Food and ...
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback